AXS-05 Phase II Trial on Smoking Behavior
A Randomized, Double-Blind 4-Week Study to Evaluate the Impact of AXS-05 on Smoking Behavior
Sponsor: Axsome Therapeutics, Inc.
Listed as NCT03471767, this PHASE2 trial focuses on Nicotine Dependence and Smoking Cessation and remains completed. Sponsored by Axsome Therapeutics, Inc., it has been updated 17 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Apr 2022 — Nov 2022 [monthly]
Completed PHASE2
▶ Show 12 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Oct 2019 — Apr 2020 [monthly]
Completed PHASE2
-
Jul 2019 — Oct 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2018 — May 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Axsome Therapeutics, Inc.
- James Davis
For direct contact, visit the study record on ClinicalTrials.gov .